the preclinical differences in therapeutic and toxicologic manifestations of 4'-epidoxorubicin , reflecting apparent alterations in pharmacologic properties and mode of action in comparison with doxorubicin , support the broad spectrum clinical trials of this already-demonstrated clinically active drug .
C0014582
epidoxorubicin
C0013089
doxorubicin